Indication | Ages 5–11 (n = 2330) | Ages 12–17 (n = 30,701) | SSRI (n = 22,130) | TCA (n = 10,489) | Any antidepressant ages 5–17 (n = 33,031) |
---|---|---|---|---|---|
Any of the pre-specified indications | 998 (42.8%) | 16,974 (55.3%) | 15,295 (69.1%) | 2463 (23.5%) | 17,972 (54.4%) |
Anxiety | 136 (5.8%) | 4019 (13.1%) | 3601 (16.3%) | 508 (4.8%) | 4155 (12.6%) |
Attention deficit hyperactivity disorder | < 10 | 61 (0.2%) | 50 (0.2%) | 14 (0.1%) | 66 (0.2%) |
Autism | 206 (8.8%) | 1020 (3.3%) | 1127 (5.1%) | 90 (0.9%) | 1226 (3.7%) |
Depression | 72 (3.1%) | 12,558 (40.9%) | 11,537 (52.1%) | 936 (8.9%) | 12,630 (38.2%) |
Enuresis | 642 (27.6%) | 308 (1.0%) | 73 (0.3%) | 877 (8.4%) | 950 (2.9%) |
Neuropathic pain | < 10 | 104 (0.3%) | < 10 | 107 (1.0%) | 113 (0.3%) |
Obsessive compulsive disorder | 53 (2.3%) | 751 (2.4%) | 774 (3.5%) | 28 (0.3%) | 804 (2.4%) |
Phobias | < 10 | 260 (0.8%) | 222 (1%) | 40 (0.4%) | 268 (0.8%) |
Self-harm | 10 (0.4%) | 2948 (9.6%) | 2715 (12.3%) | 190 (1.8%) | 2958 (9.0%) |